Fujirebio Europe N.V.

Representative image: A fully automated laboratory blood-testing workflow highlights how Fujirebio’s CE-marked Lumipulse G pTau 217 Plasma assay could support scalable Alzheimer’s disease diagnostics and expand access to biomarker-based cognitive decline evaluation across Europe.

Medical Devices & Diagnostics

Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking

by Pallavi Madhiraju
May 11, 2026
0 Comments

Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.

Read More